GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » 14-Day RSI

Rakovina Therapeutics (TSXV:RKV) 14-Day RSI : 56.46 (As of Dec. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rakovina Therapeutics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-15), Rakovina Therapeutics's 14-Day RSI is 56.46.

The industry rank for Rakovina Therapeutics's 14-Day RSI or its related term are showing as below:

TSXV:RKV's 14-Day RSI is ranked worse than
83.78% of 1523 companies
in the Biotechnology industry
Industry Median: 44.97 vs TSXV:RKV: 56.46

Competitive Comparison of Rakovina Therapeutics's 14-Day RSI

For the Biotechnology subindustry, Rakovina Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rakovina Therapeutics's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's 14-Day RSI falls into.



Rakovina Therapeutics  (TSXV:RKV) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rakovina Therapeutics  (TSXV:RKV) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Rakovina Therapeutics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Rakovina Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5
Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.
Executives
Jeffrey Bacha Senior Officer
Mads Daugaard Senior Officer
Alfredo De Lucrezia Director, Senior Officer
David Hyman Senior Officer
John Michael Langlands Senior Officer

Rakovina Therapeutics Headlines

No Headlines